...
首页> 外文期刊>Die Pharmazie >Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
【24h】

Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers.

机译:LC-ESI-MS测定阿兹尼地平及其在健康中国志愿者体内药代动力学研究中的应用。

获取原文
获取原文并翻译 | 示例
           

摘要

A simple, rapid and sensitive high performance liquid chromatography-electrospray ionization-mass spectrometry (HPLC-ESI-MS) assay for determination of azelnidipine in human plasma using perospirone as the internal standard (IS) was established. After adjustment to a basic pH with sodium hydroxide solution, plasma samples were extracted with diethyl ether and separated on a C18 column with a mobile phase of methanol-5 mM ammonium acetate solution (90:10, v/v). The lower limit of quantification (LLOQ) was 0.20 ng/ml. After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.
机译:建立了一种简单,快速,灵敏的高效液相色谱-电喷雾电离质谱(HPLC-ESI-MS)测定法,以Perospirone作为内标(IS)测定人血浆中的氮卓尼平。用氢氧化钠溶液调节至碱性pH后,血浆样品用乙醚萃取,并在C18柱上分离,流动相为甲醇-5 mM乙酸铵溶液(90:10,v / v)。定量下限(LLOQ)为0.20 ng / ml。服用单剂量的氮卓尼平后分别为8mg和16mg;从时间0 h至96 h(AUC(0-96)为(186 +/- 47)ng ml(-1)h,(429 +/- 145)ng ml(- 1)h;清除率(CL / F)分别为(45.94 +/- 11.61),(42.11 +/- 14.23)L / h;峰值血浆浓度Cmax为(8.66 +/- 1.15),(19.17) +/- 4.13)ng / ml;表观分布体积(Vd)分别为(1749 +/- 964),(2480 +/- 2212)L;达到Cmax的时间(Tmax)为(2.8 +/-)消除半衰期(t(1 / 2beta))为(2)+/-(1.2)h,(3.0 +/- 0.9)h;消除半衰期(t(1 / 2beta))分别为(22.8 +/- 2.4),(23.5 +/- 4.2)h; MRT分别为(分别为25.7 +/- 1.3),(26.2 +/- 2.2)h;口服多次给药(8 mg,qd)后的基本药代动力学参数如下:(Cmax)ss,(15.04 +/- 2.27)ng / ml;(Tmax)ss,(2.38 +/- 0.92)h;(Cmin)ss,(3.83 +/- 0.94)ng / ml; C(av),(7.05 +/- 1.54)ng / ml; DF, (1.62 +/- 0.26); AUCss,(169.19 +/- 36.87)ng ml(-1)h。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号